HOME >> BIOLOGY >> NEWS
Breast cancer patients failed by treatment with taxol and taxotere respond to abraxane

(Houston -- June 11, 2004) US Oncology (Nasdaq: USON) announced that data presented this week by a network physician at the American Society of Clinical Oncology annual meeting demonstrate that the investigational drug AbraxaneTM (albumin nanoparticle paclitaxel), administered weekly without steroid premedication, is active and well tolerated in women with metastatic breast cancer whose disease had progressed while they were treated with paclitaxel (Taxol) and/or docetaxel (Taxotere).

Based on analysis to date, results showed a 15 percent (95% CI: 8-22%) overall response rate in 106 patients who received Abraxane 100 mg/m2 administered weekly over 30 minutes a day without premedication for three weeks followed by one week of rest, with a 38 percent probability of surviving 12 months. Additionally, 40 percent of patients were free of disease progression for as long as four months, and almost 30 percent for as long as six months. Ninety-one percent of patients were able to receive the full dose throughout the study without dose reduction.

Joanne Blum, M.D., PhD., a US Oncology Principal Investigator at Texas Oncology PA (TOPA), who practices at Charles A. Sammons Cancer Center, Baylor University Medical Center in Dallas, Texas, presented the update. Charles A. Sammons Cancer Center was one of 38 US Oncology affiliated practices that had patients participate in the Abraxane clinical trial.

All patients in the trial, sponsored by American Bioscience, Inc., had progressive metastatic breast cancer while being treated with Taxol or Taxotere in the metastatic setting, or had a relapse within 12 months of adjuvant taxane therapy. The patient population studied had a poor prognosis with 91 percent having visceral (lung and liver) disease, 65 percent with more than three metastatic sites and 88 percent demonstrating ongoing tumor growth while on Taxol or Taxotere.

"The activity of Abraxane and the tolerance of the weekly reg
'"/>

Contact: Melyssa Weible
MWeible@healthstarpr.com
646-328-1457
HealthStar PR
14-Jun-2004


Page: 1 2

Related biology news :

1. Breastfeeding decreases infant mortality
2. Breast cancer study suggests role for tissue in carcinogenesis
3. Breast self examination increases womens concerns but has no effect on mortality
4. Breast cancer follow-ups no longer guess-work thanks to new physics research
5. Final media advisory for the 4th European Breast Cancer Conference (EBCC-4)
6. The 4th European Breast Cancer Conference (EBCC4)
7. Breast cancer susceptibility genes play role in DNA repair
8. Breast cancer can be reversed in laboratory mice, scientists report
9. NIH funds Breast Cancer and the Environmental Research Center at Fox Chase Cancer Center
10. Breast fluid a better option for detecting cancer
11. Breastfeeding may compensate for harmful effects of smoking during pregnancy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/11/2020)... (PRWEB) , ... February 11, 2020 , ... ... moved into The LaunchPort™ medical device accelerator in Port Covington, Baltimore. The newly ... issues that must be addressed to manage increased demand for home dialysis treatments. ...
(Date:2/7/2020)... ... February 07, 2020 , ... dicentra , ... health product, nutraceutical and dietary supplement industries, announces 2020 membership with the International ... expertise and research pertaining to probiotics. We are thrilled to join our IPA ...
(Date:2/6/2020)... ... February 06, 2020 , ... Kerafast Inc. , developers ... today announced an agreement with The Good Food Institute , a nonprofit ... the partnership, terrestrial meat and aquatic cell lines will be made available to ...
Breaking Biology News(10 mins):
(Date:2/3/2020)... ... February 03, 2020 , ... Global molecular ... that OmniType, the 11-locus, single tube multiplex successor to Holotype HLA is available ... featuring locus-multiplexing and short library preparation, for HLA genotyping from sample to answer ...
(Date:1/28/2020)... ... January 28, 2020 , ... Today, Salimetrics announced an addition ... Salivary Total Human IgG Assay Kit exemplifies Salimetrics’ 20+ year commitment ... can extend the accuracy and ease of use of salivary bioscience into infectious ...
(Date:1/24/2020)... ... January 24, 2020 , ... The plastic and reconstructive surgeons at The ... epitomize the notion that plastic surgery is much more than just cosmetic surgery and ... Over the last 20 years NJ Top Docs, Dr. Andrew Elkwood, Dr. Michael Rose, ...
(Date:1/23/2020)... ... 22, 2020 , ... Ideal Implant CEO and President Robert ... recent North American investor forums specializing in medical advancements. New technology was presented ... Forum on November 21, 2019 in New York City, and the Aesthetic Technology ...
Breaking Biology Technology:
Cached News: